The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Phase I/Ib study of parsaclisib plus standard immunochemotherapy for newly diagnosed DLBCL
Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, shares insights into a Phase I/Ib trial evaluating parsaclisib plus standard immunochemotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with high-risk features. Dr Wang highlights the rates of hematological and non-hematological toxicities observed, and the combination showed a high response rate of 98% and a progression-free survival (PFS) of 85% at two years. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
